Invivyd (NASDAQ:IVVD) Receives Buy Rating from BTIG Research

by · The Cerbat Gem

Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other brokerages have also issued reports on IVVD. Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday. HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.00.

Get Our Latest Report on Invivyd

Invivyd Price Performance

Shares of IVVD opened at $1.21 on Monday. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07. The company has a 50 day simple moving average of $1.52 and a two-hundred day simple moving average of $1.90. The firm has a market cap of $356.48 million, a P/E ratio of -3.90 and a beta of 0.71.

Invivyd (NASDAQ:IVVD – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The company had revenue of $13.74 million for the quarter, compared to analysts’ expectations of $18.04 million. On average, sell-side analysts anticipate that Invivyd will post -0.37 earnings per share for the current year.

Insider Activity at Invivyd

In other Invivyd news, insider Julie Green sold 20,964 shares of Invivyd stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the insider directly owned 107,717 shares of the company’s stock, valued at $170,192.86. The trade was a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO William E. Duke sold 20,964 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the chief financial officer owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 227,172 shares of company stock valued at $354,534 over the last three months. Corporate insiders own 12.25% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GSA Capital Partners LLP boosted its position in shares of Invivyd by 85.0% during the third quarter. GSA Capital Partners LLP now owns 805,221 shares of the company’s stock valued at $886,000 after buying an additional 369,891 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of Invivyd during the third quarter valued at $8,108,000. Two Sigma Investments LP boosted its stake in shares of Invivyd by 40.3% during the third quarter. Two Sigma Investments LP now owns 335,000 shares of the company’s stock valued at $368,000 after purchasing an additional 96,308 shares during the period. Bridgeway Capital Management LLC purchased a new stake in shares of Invivyd during the third quarter valued at $109,000. Finally, Squarepoint Ops LLC boosted its stake in shares of Invivyd by 188.9% during the third quarter. Squarepoint Ops LLC now owns 107,831 shares of the company’s stock valued at $119,000 after purchasing an additional 70,508 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

See Also